Optimal timing of rectal diclofenac in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis

Abstract

Background and study aims Rectal nonsteroidal anti-inflammatory drug (NSAID) prophylaxis reduces incidence of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Direct comparisons to the optimal timing of administration, before or after ERCP, are lacking. Therefore, we aimed to assess whether timing of rectal NSAID prophylaxis affects the incidence of post-ERCP pancreatitis.

Patients and methods We conducted an analysis of prospectively collected data from a randomized clinical trial. We included patients with a moderate to high risk of developing post-ERCP pancreatitis, all of whom received rectal diclofenac monotherapy 100-mg prophylaxis. Administration was within 30 minutes before or after the ERCP at the discretion of the endoscopist. The primary endpoint was post-ERCP pancreatitis. Secondary endpoints included severity of pancreatitis, length of hospitalization, and Intensive Care Unit (ICU) admittance.

Results We included 346 patients who received the rectal NSAID before ERCP and 63 patients who received it after ERCP. No differences in baseline characteristics were observed. Post-ERCP pancreatitis incidence was lower in the group that received pre-procedure rectal NSAIDs (8 %), compared to post-procedure (18 %) (relative risk: 2.32; 95% confidence interval: 1.21 to 4.46, P = 0.02). Hospital stays were significantly longer with post-procedure prophylaxis (1 day; interquartile range [IQR] 1–2 days vs. 1 day; IQR 1–4 days; P = 0.02). Patients from the post-procedure group were more likely to be admitted to the ICU (1 patient [0.3 %] vs. 4 patients [6 %]; P = 0.002).

Conclusions Pre-procedure administration of rectal diclofenac is associated with a significant reduction in post-ERCP pancreatitis incidence compared to post-procedure use.

Publikationsverlauf

Eingereicht: 30. Mai 2021

Angenommen: 21. September 2021

Artikel online veröffentlicht:
14. März 2022

• References

• 1 Kochar B, Akshintala VS, Afghani E. et al. Incidence, severity, and mortality of post-ERCP pancreatitis: A systematic review by using randomized, controlled trials. Gastrointest Endosc 2015; 81: 143-149.e9
• 2 Andriulli A, Loperfido S, Napolitano G. et al. Incidence rates of post-ERCP complications: A systematic survey of prospective studies. Am J Gastroenterol 2007; 102: 1781-1788
• 3 Dumonceau J-M, Kapral C, Aabakken L. et al. ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2019; 52: 127-149
• 4 Chandrasekhara V, Khashab MA, Muthusamy VR. et al. Adverse events associated with ERCP. Gastrointest Endosc 2017; 85: 32-47
• 5 Mine T, Morizane T, Kawaguchi Y. et al. Clinical practice guideline for post-ERCP pancreatitis. J Gastroenterol 2017; 52: 1013-1022
• 6 Coté GA, Elmunzer BJ. Nonsteroidal anti-inflammatory drugs for prevention of post-ERCP pancreatitis: sooner rather than later during ERCP?. Gastroenterology 2016; 151: 1027-1028
• 7 Akshintala VS, Hutfless SM, Colantuoni E. et al. Systematic review with network meta-analysis: pharmacological prophylaxis against post-ERCP pancreatitis. Aliment Pharmacol Ther 2013; 38: 1325-1337
• 8 Fogel EL, Lehman GA, Tarnasky P. et al. Rectal indometacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients: a double-blind, randomized controlled trial. Lancet Gastroenterol Hepatol 2020; 5: 132-141
• 9 Yoshihara T, Horimoto M, Kitamura T. et al. 25 mg versus 50 mg dose of rectal diclofenac for prevention of post-ERCP pancreatitis in Japanese patients: A retrospective study. BMJ Open 2015; 5: 1-6
• 10 Lai JH, Hung CY, Chu CH. et al. A randomized trial comparing the efficacy of single-dose and double-dose administration of rectal indomethacin in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis. Medicine (Baltimore) 2019; 98: e15742
• 11 Katoh T, Kawashima K, Fukuba N. et al. Low-dose rectal diclofenac does not prevent post-ERCP pancreatitis in low- or high-risk patients. J Gastroenterol Hepatol 2020; 35: 1247-1253
• 12 Liu L, Li C, Huang Y. et al. Nonsteroidal Anti-inflammatory drugs for endoscopic retrograde cholangiopancreatography postoperative pancreatitis prevention: a systematic review and meta-analysis. J Gastrointest Surg 2019; 23: 1991-2001
• 13 Yang C, Zhao Y, Li W. et al. Rectal nonsteroidal anti-inflammatory drugs administration is effective for the prevention of post-ERCP pancreatitis: An updated meta-analysis of randomized controlled trials. Pancreatology 2017; 17: 681-688
• 14 Patai Á, Solymosi N, Mohácsi L. et al. Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled trials. Gastrointest Endosc 2017; 85: 1144-1156.e1
• 15 Ding X, Chen M, Huang S. et al. Nonsteroidal anti-inflammatory drugs for prevention of post-ERCP pancreatitis: A meta-analysis. Gastrointest Endosc 2012; 76: 1252-1259
• 16 Wan J, Ren Y, Zhu Z. et al. How to select patients and timing for rectal indomethacin to prevent post-ERCP pancreatitis: A systematic review and meta-analysis. BMC Gastroenterol 2017; 17: 1-9
• 17 Rustagi T, Njei B. Factors affecting the efficacy of nonsteroidal anti-inflammatory drugs in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis. Pancreas 2015; 44: 859-867
• 18 Sun HL, Han B, Zhai HP. et al. Rectal NSAIDs for the prevention of post-ERCP pancreatitis: A meta-analysis of randomized controlled trials. Surgeon 2014; 12: 141-147
• 19 Sperna Weiland CJ, Smeets XJNM, Kievit W. et al. Aggressive fluid hydration plus non-steroidal anti-inflammatory drugs versus non-steroidal anti-inflammatory drugs alone for post-endoscopic retrograde cholangiopancreatography pancreatitis (FLUYT): a multicentre, open-label, randomised, controlled trial. Lancet Gastroenterol Hepatol 2021; 5: 350-358
• 20 Vandenbroucke JP, Von Elm E, Altman DG. et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. Epidemiology 2007; 18: 805-835
• 21 Schneider A, Löhr JM, Singer MV. The M-ANNHEIM classification of chronic pancreatitis: Introduction of a unifying classification system based on a review of previous classifications of the disease. J Gastroenterol 2007; 42: 101-119
• 22 Buxbaum J, Yan A, Yeh K. et al. Aggressive hydration with lactated ringer’s solution reduces pancreatitis after endoscopic retrograde cholangiopancreatography. Clin Gastroenterol Hepatol 2014; 12: 303-307.e1
• 23 Elmunzer BJ, Scheiman JM, Lehman GA. et al. A Randomized Trial of Rectal Indomethacin to Prevent Post-ERCP Pancreatitis. N Engl J Med 2012; 366: 1414-1422
• 24 Cotton PB, Lehman G, Vennes J. et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37: 383-393
• 25 Banks PA, Bollen TL, Dervenis C. et al. Classification of acute pancreatitis – 2012: Revision of the Atlanta classification and definitions by international consensus. Gut 2013; 62: 102-111
• 26 Yang J, Wang W, Liu C. et al. Rectal nonsteroidal anti-inflammatory drugs for endoscopic retrograde cholangiopancreatography postoperative pancreatitis prevention: a network meta-analysis. J Clin Gastroenterol 2020; 54: 305-313
• 27 Luo H, Zhao L, Leung J. et al. Routine pre-procedural rectal indometacin versus selective post-procedural rectal indometacin to prevent pancreatitis in patients undergoing endoscopic retrograde cholangiopancreatography: a multicentre, single-blinded, randomised controlled trial. Lancet 2016; 387: 2293
• 28 Tammaro S, Caruso R, Pallone F. et al. Post-endoscopic retrograde cholangio-pancreatography pancreatitis: Is time for a new preventive approach?. World J Gastroenterol 2012; 18: 4635-4638
• 29 Van Der Marel CD, Anderson BJ, Rømsing J. et al. Diclofenac and metabolite pharmacokinetics in children. Paediatr Anaesth 2004; 14: 443-451
• 30 Cuthbertson CM, Christophi C. Disturbances of the microcirculation in acute pancreatitis. Br J Surg 2006; 93: 518-530
• 31 Elmunzer BJ, Scheiman MJ, Lehman AG. et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012; 366: 1414-1422
• 32 Sethi S, Sethi N, Wadhwa V. et al. A meta-analysis on the role of rectal diclofenac and indomethacin in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas 2014; 43: 190-197
• 33 Puig I, Calvet X, Baylina M. et al. How and when should NSAIDs be used for preventing post-ERCP pancreatitis? A systematic review and meta-analysis. PLoS One 2014; 9: 1-8
• 34 Leerhøy B, Nordholm-Carstensen A, Novovic S. et al. Effect of body weight on fixed dose of diclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Scand J Gastroenterol 2016; 51: 1007-1012
• 35 Cotton PB, Calvet X, Eisen G, Romagnuolo J. et al. Grading the complexity of endoscopic procedures: results of an ASGE working party. Gastrointest Endosc 2011; 73: 868-874